- Home
- GIGM vs SIGA Comparison
GIGM vs SIGA Comparison
Compare GIGM & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GIGM
- SIGA
- Stock Information
- Founded
- GIGM 1998
- SIGA 1995
- Country
- GIGM Taiwan
- SIGA United States
- Employees
- GIGM N/A
- SIGA N/A
- Industry
- GIGM Computer Software: Programming Data Processing
- SIGA Biotechnology: Pharmaceutical Preparations
- Sector
- GIGM Technology
- SIGA Health Care
- Exchange
- GIGM Nasdaq
- SIGA Nasdaq
- Market Cap
- GIGM 17.0M
- SIGA 515.1M
- IPO Year
- GIGM 2000
- SIGA 1997
- Fundamental
- Price
- GIGM $1.86
- SIGA $9.00
- Analyst Decision
- GIGM
- SIGA
- Analyst Count
- GIGM 0
- SIGA 0
- Target Price
- GIGM N/A
- SIGA N/A
- AVG Volume (30 Days)
- GIGM 23.8K
- SIGA 513.2K
- Earning Date
- GIGM 10-29-2025
- SIGA 11-06-2025
- Dividend Yield
- GIGM N/A
- SIGA 6.67%
- EPS Growth
- GIGM N/A
- SIGA N/A
- EPS
- GIGM N/A
- SIGA 1.14
- Revenue
- GIGM $3,250,000.00
- SIGA $179,639,422.00
- Revenue This Year
- GIGM N/A
- SIGA N/A
- Revenue Next Year
- GIGM N/A
- SIGA $115.06
- P/E Ratio
- GIGM N/A
- SIGA $7.89
- Revenue Growth
- GIGM N/A
- SIGA 3.86
- 52 Week Low
- GIGM $1.30
- SIGA $4.95
- 52 Week High
- GIGM $1.89
- SIGA $9.62
- Technical
- Relative Strength Index (RSI)
- GIGM 73.25
- SIGA 61.23
- Support Level
- GIGM $1.61
- SIGA $8.49
- Resistance Level
- GIGM $1.87
- SIGA $9.09
- Average True Range (ATR)
- GIGM 0.09
- SIGA 0.30
- MACD
- GIGM 0.03
- SIGA -0.01
- Stochastic Oscillator
- GIGM 92.88
- SIGA 83.51
About GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. Its only segment and principal business is digital entertainment service business, which operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. It operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.